Management to hold a conference call at 10:00 a.m. EDT
TEL AVIV, Israel--(BUSINESS WIRE)--Aug. 13, 2015--
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that it
will release its unaudited financial results for the quarter ended June
30, 2015 on Thursday, August 20, 2015, before the U.S. markets open.
The Company will host a conference call on Thursday, August 20 at 10:00
a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive
Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating
Officer of BioLineRx. The conference call will be available via webcast
and can be accessed through the Investor Relations section of
BioLineRx’s website, www.biolinerx.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-668-9141 from the U.S. or
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will be available until August 23, 2015;
please dial 1-888-782-4291 from the U.S. or +972-3-925-5925
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-8040, a cancer therapy platform,
which is in the midst of a Phase 2 study for acute myeloid leukemia
(AML), and has successfully completed a Phase 1 study in stem cell
mobilization; BL-7010 for celiac disease, which has successfully
completed a Phase 1/2 study; and BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria).
In December 2014, BioLineRx entered into a strategic collaboration with
Novartis for the co-development of selected Israeli-sourced novel drug
candidates. The companies intend to co-develop a number of pre-clinical
and early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150813005403/en/
Source: BioLineRx Ltd.
Strategic Advisors, Inc.
Joshua Drumm, Ph.D., +1-212-375-2664
Tsipi Haitovsky, +972-3-6240871